REGISTERED
on 04 Feb 2020
Last Applicant/ Owned by
Sycamore House,
GB
Serial Number
79252849 filed on 19th Nov 2018
Registration Number
5974485 registered on 04th Feb 2020
Correspondent Address
Samantha M. Quimby
Filing Basis
No Filing Basis
Disclaimer
NO DATA
FREELINE
Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others P Read More
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
Class [040]
Treatment & Processing of Materials Services
Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others
Mark Details
Serial Number
No 79252849
Mark Type
No Service Mark
Attorney Docket Number
No 0641296
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 04th Feb 2023 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| 06th Aug 2022 | NEW REPRESENTATIVE AT IB RECEIVED |
| 05th Jun 2020 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| 18th May 2020 | FINAL DISPOSITION NOTICE SENT TO IB |
| 18th May 2020 | FINAL DISPOSITION PROCESSED |
| 04th May 2020 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 04th Feb 2020 | REGISTERED-PRINCIPAL REGISTER |
| 19th Nov 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 19th Nov 2019 | PUBLISHED FOR OPPOSITION |
| 15th Nov 2019 | NOTIFICATION PROCESSED BY IB |